Supernus Pharmaceuticals Inc
NASDAQ:SUPN

Watchlist Manager
Supernus Pharmaceuticals Inc Logo
Supernus Pharmaceuticals Inc
NASDAQ:SUPN
Watchlist
Price: 46.84 USD -0.68%
Market Cap: 2.7B USD

Intrinsic Value

The intrinsic value of one SUPN stock under the Base Case scenario is 67.85 USD. Compared to the current market price of 46.84 USD, Supernus Pharmaceuticals Inc is Undervalued by 31%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

SUPN Intrinsic Value
67.85 USD
Undervaluation 31%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Supernus Pharmaceuticals Inc

What is Valuation History?
Ask AI Assistant
What other research platforms think about SUPN?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is SUPN valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Supernus Pharmaceuticals Inc.

Explain Valuation
Compare SUPN to

Fundamental Analysis

Company Overview
Loading...
Business Segments
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about SUPN?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Supernus Pharmaceuticals Inc

Current Assets 593.9m
Cash & Short-Term Investments 281.2m
Receivables 171.3m
Other Current Assets 141.5m
Non-Current Assets 825.9m
PP&E 39.4m
Intangibles 742.6m
Other Non-Current Assets 43.9m
Current Liabilities 330.6m
Accounts Payable 116.8m
Accrued Liabilities 284.9m
Other Current Liabilities -71.1m
Non-Current Liabilities 39.5m
Other Non-Current Liabilities 39.5m
Efficiency

Free Cash Flow Analysis
Supernus Pharmaceuticals Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Supernus Pharmaceuticals Inc

Revenue
681.5m USD
Cost of Revenue
-68.8m USD
Gross Profit
612.8m USD
Operating Expenses
-571.3m USD
Operating Income
41.5m USD
Other Expenses
-60.6m USD
Net Income
-19.1m USD
Fundamental Scores

SUPN Profitability Score
Profitability Due Diligence

Supernus Pharmaceuticals Inc's profitability score is 46/100. The higher the profitability score, the more profitable the company is.

Exceptional Gross Margin
Strong 3Y Average Gross Margin
ROIC is Increasing
Operating Margin is Increasing
46/100
Profitability
Score

Supernus Pharmaceuticals Inc's profitability score is 46/100. The higher the profitability score, the more profitable the company is.

SUPN Solvency Score
Solvency Due Diligence

Supernus Pharmaceuticals Inc's solvency score is 75/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Low D/E
Long-Term Solvency
Short-Term Solvency
75/100
Solvency
Score

Supernus Pharmaceuticals Inc's solvency score is 75/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

SUPN Price Targets Summary
Supernus Pharmaceuticals Inc

Wall Street analysts forecast SUPN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for SUPN is 61.71 USD with a low forecast of 50.5 USD and a high forecast of 68.25 USD.

Lowest
Price Target
50.5 USD
8% Upside
Average
Price Target
61.71 USD
32% Upside
Highest
Price Target
68.25 USD
46% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Supernus Pharmaceuticals Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for SUPN is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

SUPN Insider Trading
Buy and sell transactions by insiders

What is the Intrinsic Value of one SUPN stock?

The intrinsic value of one SUPN stock under the Base Case scenario is 67.85 USD.

Is SUPN stock undervalued or overvalued?

Compared to the current market price of 46.84 USD, Supernus Pharmaceuticals Inc is Undervalued by 31%.

Back to Top